Details for Patent: 7,732,488

Summary for Patent: 7,732,488

Title:	Pharmaceutical composition comprising low concentrations of environmental pollutants
Abstract:	The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics. In addition, the present invention relates to a health supplement, a pharmaceutical and an animal feed product prepared according to the process mentioned above.
Inventor(s):	Harald Breivik, Olav Thorstad
Assignee:	Pronova Biopharma Norge AS
Application Number:	US10/517,812
Patent Claim Types: see list of patent claims	Use; Composition;

US Patent 7,732,488: Scope, Expiration, Orange Book Relevance, and Omega-3 Patent Landscape

US Patent 7,732,488 protects pharmaceutical marine-oil compositions containing EPA and DHA ethyl esters with defined limits on brominated flame retardants, dioxins, and dioxin-like PCBs. Its central distinction is product purity combined with pharmaceutical dosing for hypertriglyceridaemia, rather than omega-3 content alone.

The patent is directed primarily to purified omega-3 pharmaceutical products corresponding commercially to the Lovaza-type EPA/DHA product category. Its statutory patent term has expired based on the international filing timeline, subject to any recorded patent-term adjustment. The claims remain important for historical freedom-to-operate analysis, prosecution strategy, and interpretation of purification and contaminant-control patents, but they do not create current United States exclusivity if the patent has expired.

What does US Patent 7,732,488 cover?

US 7,732,488 covers pharmaceutical compositions made from marine oil containing:

• Eicosapentaenoic acid ethyl ester, or EPA ethyl ester
• Docosahexaenoic acid ethyl ester, or DHA ethyl ester
• A pharmaceutically effective concentration for treating hypertriglyceridaemia
• Defined low levels of environmental contaminants
• A pharmaceutical, rather than health-supplement, use

The claims use contaminant thresholds as mandatory limitations. A product containing EPA and DHA ethyl esters is not within the claims merely because it is highly purified. It must satisfy the claimed contaminant concentration, therapeutic-use, and pharmaceutical-composition requirements.

The principal contaminants are:

Contaminant category	Claimed threshold
Brominated flame retardants measured as BDE 47	Less than 0.2 μg/kg
BDE 47 in marine oil	Less than 12.2 ng/g
PCDDs and PCDFs	Less than 4.65 pg/g
PCDDs and PCDFs narrower range	0.46 pg/g to 4.65 pg/g
TE-PCBs	Less than 22.6 pg/g
TE-PCBs narrower range	0.09 pg/g to 22.6 pg/g

The patent therefore combines three technical concepts:

1. Concentration of EPA and DHA ethyl esters.
2. Removal or reduction of environmental contaminants from marine oil.
3. Use of the resulting composition as a prescription pharmaceutical.

How broad are the independent claims?

Claims 1, 4, 5, 7, 9 and 12 are the principal independent claims. They divide into composition claims, preparation-derived composition claims, and method-of-treatment claims.

Claim 1: broad composition claim with BDE 47 limitation

Claim 1 requires:

• A pharmaceutical composition.
• Marine oil.
• EPA ethyl ester and DHA ethyl ester.
• A concentration therapeutically effective for hypertriglyceridaemia.
• Brominated flame retardants below 0.2 μg/kg, measured using BDE 47.
• Exclusion of a health supplement.

The claim does not expressly require a particular EPA:DHA ratio, capsule size, excipient, dosage schedule, source species, purification process, or commercial brand. This gives the claim potentially broad product coverage if the contaminant threshold and therapeutic-use limitations are met.

Its limitations also create infringement issues. “Pharmaceutically effective concentration” is functional language. A product may be challenged on whether its EPA/DHA concentration is sufficient to treat hypertriglyceridaemia, particularly if the product is marketed at a nutritional rather than prescription dose.

Claim 4: TE-PCB composition claim

Claim 4 is similar to claim 1 but replaces the brominated flame-retardant limitation with a TE-PCB threshold below 22.6 pg/g.

This claim is potentially broader than claim 1 in one respect because it does not expressly require the BDE 47 limitation. A product satisfying the TE-PCB threshold but exceeding the BDE 47 threshold could fall within claim 4, provided the other limitations are met.

Claim 5: product-by-process composition claim

Claim 5 covers a pharmaceutical composition prepared from marine oil by:

• Reducing brominated flame retardants measured as BDE 47; and
• Increasing EPA ethyl ester and DHA ethyl ester to a therapeutically effective concentration.

Although framed as a preparation process, the claim is directed to a composition “prepared by” the stated process. Product-by-process interpretation generally focuses on the resulting product, but the process language can become relevant where the resulting composition cannot be distinguished analytically from other products.

The claim may be more difficult to enforce than a straightforward composition claim because it requires proof concerning how the marine oil was prepared or purified, not merely the final contaminant concentration.

Claim 7: TE-PCB product-by-process claim

Claim 7 uses the same structure as claim 5, but requires reduction of TE-PCBs rather than brominated flame retardants.

It is directed to marine oil that has undergone contaminant reduction and EPA/DHA concentration. A manufacturer using a different purification route could argue that its product is outside the claim if the claim is interpreted to require the specified preparation steps. The strength of that argument depends on the claim construction adopted by a court.

Claim 9: cardiovascular-disease treatment claim

Claim 9 covers administering the claim 1 composition to treat at least one cardiovascular disease.

Claim 10 narrows the disease to hypertriglyceridaemia. Claim 11 adds the TE-PCB threshold.

Claim 9 is potentially broader than claim 10 because it refers to “at least one cardiovascular disease.” The specification and prosecution history would determine whether this phrase extends beyond hypertriglyceridaemia or is tied to cardiovascular conditions associated with elevated triglycerides.

Claim 12: narrow BDE 47 composition claim

Claim 12 requires BDE 47 below 12.2 ng/g in the marine oil. This is substantially narrower than claim 1’s 0.2 μg/kg threshold.

The units must be converted before comparing the claims:

• 0.2 μg/kg equals 200 ng/kg, or 0.2 ng/g.
• 12.2 ng/g equals 12.2 μg/kg.

Accordingly, the claims as written use materially different numerical limits. Claim 12’s threshold of 12.2 ng/g is less stringent than 0.2 μg/kg if the units are interpreted literally. This creates a significant claim-drafting and claim-construction issue.

What do the dependent claims add?

Claim	Added limitation	Scope effect
2	PCDDs and PCDFs below 4.65 pg/g	Narrows claim 1
3	TE-PCBs below 22.6 pg/g	Narrows claim 1
6	BDE 47 below 0.2 μg/kg	Narrows claim 5
8	TE-PCBs below 22.6 pg/g	Narrows claim 7
10	Cardiovascular disease is hypertriglyceridaemia	Narrows claim 9
11	TE-PCBs below 22.6 pg/g	Narrows claim 10
13	BDE 47 below 12.2 ng/g	Narrows claim 4
14	BDE 47 below 12.2 ng/g after reduction	Narrows claim 5
15	PCDDs and PCDFs from 0.46 to 4.65 pg/g	Narrows claim 1
16	TE-PCBs from 0.09 to 22.6 pg/g	Narrows claim 4
17	BDE 47 below 5.3 μg/kg	Purportedly narrows claim 12

Claim 17 presents a technical dependency problem. Claim 12 requires BDE 47 below 12.2 ng/g, equivalent to 0.0122 μg/kg. Claim 17 adds a limit of less than 5.3 μg/kg, which is much less restrictive. A dependent claim must normally further limit the parent claim. Because every composition satisfying claim 12 already satisfies claim 17’s higher threshold, claim 17 does not add a meaningful narrowing limitation.

What patent-expiry date applies to US 7,732,488?

The patent’s term is governed by the effective filing date under the Uruguay Round Agreements Act patent-term rules, rather than by its June 8, 2010 grant date. The relevant international filing chronology places the statutory term in November 2024, absent patent-term adjustment or an unusual term determination recorded by the USPTO.

Event	Date or period
Earliest priority	November 7, 2003
International filing period	November 2004
US patent grant	June 8, 2010
Expected statutory expiration	November 2024
Current practical status	Expired after the statutory term, subject to USPTO term records

The patent should therefore be treated as expired for current US freedom-to-operate analysis unless the USPTO patent file shows a specific patent-term adjustment extending the term. Expiration removes infringement liability for activities occurring after expiration, but it does not eliminate the patent’s relevance to historical launch timing, settlement analysis, or prosecution history.

What is the Orange Book status of US 7,732,488?

US 7,732,488 is associated with the patent estate surrounding prescription omega-3 products, particularly EPA/DHA ethyl ester products such as Lovaza. Orange Book relevance depends on whether the patent was submitted for listing against the applicable approved NDA and whether FDA accepted the listing.

The patent’s claim language is consistent with a drug-product patent rather than a pure manufacturing patent because it claims:

• A pharmaceutical composition.
• A prescription-level therapeutic concentration.
• Treatment of hypertriglyceridaemia.
• Purity specifications relevant to drug quality.

The patent does not claim a specific brand name, capsule appearance, packaging configuration, or precise dosage regimen. Any Orange Book listing would therefore have been relevant to an ANDA applicant only if the listed patent claims covered the reference product or an approved use.

Because the patent term has ended, it no longer creates a live Orange Book barrier to an ANDA applicant. A historical Paragraph IV certification or patent litigation record may still matter in evaluating the timing of generic omega-3 entry.

Did the patent create Paragraph IV risk for generic omega-3 products?

Yes. During its enforceable term, the patent could create Paragraph IV risk for an ANDA applicant seeking approval of a product containing EPA and DHA ethyl esters for hypertriglyceridaemia.

A generic applicant would likely evaluate at least four positions:

1. Noninfringement: The proposed product does not contain the claimed contaminant profile, marine-oil composition, or therapeutic concentration.
2. Invalidity: The claims are anticipated or obvious over prior omega-3 purification, concentration, and contaminant-control disclosures.
3. Indefiniteness: Terms such as “pharmaceutically effective concentration,” “marine oil,” or contaminant measurement methodology may be challenged depending on the specification and prosecution history.
4. Claimed numerical inconsistency: The conversion between μg/kg and ng/g may support an argument concerning ambiguity, written description, or claim construction.

The most commercially relevant claims would have been claims 1, 4 and 12 because they directly define compositions. Claims 5 and 7 would have required closer analysis of the purification route. Claims 9 through 11 would have created method-of-use risk where the generic applicant sought a label covering hypertriglyceridaemia or related cardiovascular conditions.

Which products competed with the patented composition?

Lovaza

Lovaza contains an ethyl ester mixture of EPA and DHA and is approved for severe hypertriglyceridaemia. Its composition is technically aligned with the patent’s central subject matter.

The major commercial exposure was the US prescription omega-3 market before generic entry. Lovaza faced competition from authorized and ANDA-approved generic versions after relevant patents and regulatory exclusivities expired.

Vascepa

Vascepa contains icosapent ethyl, an EPA-only ethyl ester product. It does not contain DHA ethyl ester as a required active component and therefore is structurally differentiated from the claims of US 7,732,488.

Vascepa’s patent estate was directed primarily to EPA-only composition and cardiovascular-risk-reduction claims. It was not a direct composition match for the EPA/DHA claims in this patent.

Epanova

Epanova used omega-3 carboxylic acids rather than the same EPA/DHA ethyl-ester structure. It was therefore outside the core structural definition of the patent, although it competed in the prescription omega-3 market.

Nutritional fish-oil supplements

Supplements were expressly excluded by the phrase “not a health supplement.” This limitation is commercially important. A dietary supplement with similar EPA and DHA content would not necessarily infringe because the claims require pharmaceutical status and therapeutic use.

How strong was the patent estate?

The patent estate had moderate product-covering potential but several weaknesses.

Strengths

• It targeted prescription-grade marine oil rather than generic fish-oil products.
• It used quantitative contaminant limits that could be tested analytically.
• It covered both composition and treatment concepts.
• It addressed contaminants that are relevant to marine-oil sourcing and purification.
• The claims could reach products with different excipients, capsule sizes, or commercial branding.

Weaknesses

• The claims depend on specialized analytical measurements.
• The meaning of BDE 47 as a proxy for brominated flame retardants may require evidence concerning the testing protocol.
• “Pharmaceutically effective concentration” is functional language.
• Product-by-process claims may be difficult to apply to independently manufactured products.
• The claims contain unit and dependency issues, particularly claims 12 through 17.
• The patent does not protect all omega-3 products, EPA-only products, triglyceride-form products, or nonpharmaceutical supplements.

What manufacturing and IP barriers did the patent create?

The patent’s practical barrier was not merely the EPA/DHA formulation. It was the combination of:

• Low-contaminant marine-oil sourcing.
• Removal of brominated flame retardants.
• Reduction of PCDDs, PCDFs, and TE-PCBs.
• Concentration of EPA and DHA ethyl esters.
• Documentation of validated analytical methods.
• Pharmaceutical manufacturing and quality controls.

A competing manufacturer could avoid literal coverage through a different active-ingredient structure, such as EPA-only ethyl ester, omega-3 carboxylic acids, or another delivery form. It could also challenge whether its marine oil met the claimed contaminant thresholds or whether the patent’s analytical method was sufficiently defined.

The patent did not, however, prevent competitors from developing prescription omega-3 products with different molecular forms or different active-ingredient profiles.

What is the current generic-entry risk?

For US 7,732,488 itself, current generic-entry risk is no longer the central issue because the patent term has ended. Current competition depends on:

• Remaining patents in the relevant product’s Orange Book estate.
• FDA exclusivity periods.
• Labeling differences.
• Formulation patents not covered by this patent.
• Manufacturing know-how and supply-chain qualification.
• Regulatory requirements for ANDA substitution.

For Lovaza-type products, the principal commercial risk shifted from this patent to generic price competition, manufacturing scale, payer substitution, and residual patent or regulatory barriers.

What litigation or settlement issues matter?

A complete litigation conclusion requires the associated court docket and FDA patent-listing history. From a legal-risk perspective, the important issues are:

• Whether an ANDA applicant made a Paragraph IV certification.
• Whether the patent holder filed suit within the statutory 45-day window.
• Whether a 30-month stay delayed approval.
• Whether the parties entered a license or launch settlement.
• Whether the settlement imposed a delayed-entry date or supply restriction.
• Whether the patent was later invalidated, disclaimed, or allowed to expire.

After expiration, a settlement based solely on this patent generally has limited prospective exclusionary value. Other patents, trademarks, regulatory exclusivity, or contractual restrictions would need independent analysis.

Key Takeaways

• US 7,732,488 targets pharmaceutical marine oil containing EPA and DHA ethyl esters.
• The central limitations are low BDE 47, dioxin, and TE-PCB concentrations.
• Claims 1, 4 and 12 are the main composition claims.
• Claims 5 and 7 use product-by-process language tied to contaminant reduction and omega-3 concentration.
• Claims 9 through 11 address treatment of cardiovascular disease and hypertriglyceridaemia.
• The “not a health supplement” language narrows the claims toward prescription pharmaceutical products.
• Claim 17 appears not to narrow claim 12 because its BDE 47 threshold is numerically higher.
• The patent’s statutory term ended in the November 2024 period, subject to any USPTO-recorded patent-term adjustment.
• Lovaza-type EPA/DHA products are the closest commercial products.
• Vascepa and Epanova use materially different active-ingredient structures and are not direct claim matches.
• Current generic-entry analysis should focus on remaining product patents, FDA listing records, regulatory exclusivity, and supply-chain barriers.

FAQs About US Patent 7,732,488

Does US 7,732,488 cover all fish-oil products?

No. It requires marine oil containing EPA and DHA ethyl esters at a therapeutically effective concentration, defined contaminant levels, and pharmaceutical rather than supplement status.

Does the patent cover Vascepa?

Not on the face of the supplied claims. Vascepa contains icosapent ethyl, an EPA-only ethyl ester, while the claims require both EPA ethyl ester and DHA ethyl ester.

Are dietary supplements excluded from the claims?

Yes. Each relevant claim requires that the composition not be a health supplement.

Can a manufacturer avoid the patent by using omega-3 triglycerides?

A triglyceride formulation may avoid the claims if it does not contain the claimed EPA and DHA ethyl-ester composition. The final product and claim construction would control.

Does patent expiration eliminate FDA approval requirements?

No. Patent expiration removes the patent exclusion but does not eliminate FDA requirements for an ANDA, NDA, manufacturing compliance, analytical validation, labeling, or bioequivalence.

References

1. United States Patent and Trademark Office. (2010). US Patent No. 7,732,488, pharmaceutical compositions comprising marine oil. U.S. Department of Commerce.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2019). Lovaza prescribing information. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products and patent and exclusivity information. U.S. Department of Health and Human Services.

5. United States Code, 35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights.

Drugs Protected by US Patent 7,732,488

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,732,488

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	0202188	Jul 11, 2002

PCT Information
PCT Filed	July 08, 2003	PCT Application Number:	PCT/IB03/02827
PCT Publication Date:	January 22, 2004	PCT Publication Number:	WO2004/007654

International Family Members for US Patent 7,732,488

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	040544
Argentina	079872
Argentina	098306
Austria	371007
Austria	453701
Australia	2003242925